Familial Hypercholesterolemia: Screening, Diagnosis, and Treatment

A genetic condition that raises cholesterol from birth has one defining feature for the family physician: it travels through families. This American Family Physician editorial leans into that fact, framing familial hypercholesterolemia as a problem best solved not one patient at a time but one family at a time.

The condition is an autosomal dominant disorder — meaning each first-degree relative of an affected person has a coin-flip chance of carrying it. Yet the common heterozygous form shows no outward signs and is typically diagnosed only after an early heart attack. That combination, invisible but inheritable, is exactly why a family-centered approach matters.

The editorial’s practical core is cascade screening: when one case is found, systematically test parents, siblings, and children, where the diagnostic yield is far higher than in the general population. It pairs this with the Dutch Criteria as a structured diagnostic tool, LDL thresholds for triggering genetic testing (above 190 mg/dL in adults, 155 in children), and the AHA’s endorsement of screening at ages 9 to 11. Treatment runs from lifestyle and statins up through PCSK9 inhibitors and newer agents, with early intervention aimed at the events that otherwise strike before 50.

The friction, as with all FH screening, is the unresolved disagreement over screening children — the USPSTF finds the evidence insufficient while pediatric and cardiology bodies recommend it.

We rate the evidence moderate-to-solid for what it is: a peer-reviewed editorial built on guidelines and primary literature, not original research. Its real contribution is operational — turning a diagnosis into a search strategy that follows the gene through the family tree.